ArticleSchizophrenia research2020
Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study.
Article in Schizophrenia research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Evidence-based atlas of risk and protective factors for psychotic disorders: an umbrella review to inform personalized prognosis and prevention.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Psychosis Polyrisk Score and Polygenic Risk Score to Improve Detection and Prognosis in Individuals at Clinical High Risk for Psychosis: Model Development and Internal Validation.Schizophrenia bulletin · 2026Article
- Exploring the use of machine and deep learning in genome-wide association studies: a comprehensive review.BioData mining · 2026Review
- Association between the Korea-Polyenvironmental Risk Score and Clinical Outcomes in Schizophrenia Spectrum Disorders.Schizophrenia bulletin · 2026Article
- Combining the Risk: The Poly-Environmental Risk Score and Psychotic Symptoms in Adolescents.Schizophrenia bulletin · 2025Article
- Associations of polygenic risk score, environmental factors, and their interactions with the risk of schizophrenia spectrum disorders.Psychological medicine · 2025Article
- Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
- The ENTER study (E-DetectioN Tool for Emerging Mental DisoRders): general population recruitment and data integrity in online screening for psychosis risk.Frontiers in psychiatry · 2025Article
- Impacts of Polyenvironmental Factors on DNA Methylation in Patients With Psychosis.Schizophrenia bulletin open · 2025Article
- Exploring causal mechanisms of psychosis risk.Neuroscience and biobehavioral reviews · 2024Review
- The Translational Future of Stress Neurobiology and Psychosis Vulnerability: A Review of the Evidence.Current neuropharmacology · 2024Review
- Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis.Schizophrenia (Heidelberg, Germany) · 2022Article
- Development of the Korea-Polyenvironmental Risk Score for Psychosis.Psychiatry investigation · 2022Article
- Mapping the implementation and challenges of clinical services for psychosis prevention in England.Frontiers in psychiatry · 2022Article
- Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021Article
- Preventive psychiatry: a blueprint for improving the mental health of young people.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021Article
- Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients.Translational psychiatry · 2020Article
- The Role of Gut Microbiota in the High-Risk Construct of Severe Mental Disorders: A Mini Review.Frontiers in psychiatry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 6 countries.
Funding
Abstract
backgroundThe Psychosis Polyrisk Score (PPS) is a potential biomarker integrating non-purely genetic risk/protective factors for psychosis that may improve identification of individuals at risk and prediction of their outcomes at the individual subject level. Biomarkers that are easy to administer are direly needed in early psychosis to facilitate clinical implementation. This study digitally implements the PPS and pilots its feasibility of use in the real world.
methodsThe PPS was implemented digitally and prospectively piloted across individuals referred for a CHR-P assessment (n = 16) and healthy controls (n = 66). Distribution of PPS scores was further simulated in the general population.
results98.8% of individuals referred for a CHR-P assessment and healthy controls completed the PPS assessment with only one drop-out. 96.3% of participants completed the assessment in under 15 min. Individuals referred for a CHR-P assessment had high PPS scores (mean = 6.2, SD = 7.23) than healthy controls (mean = -1.79, SD = 6.78, p < 0.001). In simulated general population data, scores were normally distributed ranging from -15 (lowest risk, RR = 0.03) to 39.5 (highest risk, RR = 8912.51). DISCUSSION: The PPS is a promising biomarker which has been implemented digitally. The PPS can be easily administered to both healthy controls and individuals at potential risk for psychosis on a range of devices. It is feasible to use the PPS in real world settings to assess individuals with emerging mental disorders. The next phase of research should be to include the PPS in large-scale international cohort studies to evaluate its ability to refine the prognostication of outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.